We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Privacy Terms and Cookie Policy
Shining Light on Farm & Food Policy for 20 Years.
Sunday, November 24, 2024
In this opinion piece, Jerold Mande and Thomas Grumbly of Nourish Science discuss why USDA is positioned to lead the development and implementation of federal diet and health strategy by consolidating several fragmented programs at FDA and USDA.
The Food and Drug Administration will use an outside evaluation released Tuesday to help reform its human foods program, FDA Commissioner Robert Califf said following release of the report by the Reagan-Udall Foundation.
USDA is taking steps to accelerate some of the $18 billion in new conservation funding provided by the Inflation Reduction Act for climate-related farming practices.
The Food and Drug Administration is considering setting up a dedicated cadre of investigators for infant formula production as part of a strategy to prevent contamination of the product.
The Food and Drug Administration has proposed a rule laying out recordkeeping requirements for foods that could be linked to foodborne disease outbreaks.
A new U.S. Government Accountability Office report suggested the FDA commissioner should direct the agency to track the dates of the last pre- and postmarket reviews for all food contact substances in a way that allows FDA to readily identify substances that may warrant postmarket review.
In this opinion piece, Jennifer McEntire, Ph.D., with the International Fresh Produce Association discusses the present state of the foods programs at FDA and a call for the Agency to make a cultural shift.
Is a seaweed feed additive which can significantly reduce methane emissions considered a feed ingredient or animal drug? What about an animal food ingredient which could actually reduce the risk of salmonella? According to current Food and Drug Administration policy, the answer is an animal drug, adding years and additional cost to gain approval from FDA.